Research programme: G protein-coupled receptor modulators - Paradigm Therapeutics
Latest Information Update: 13 Feb 2008
Price :
$50 *
At a glance
- Originator Paradigm Therapeutics
- Developer Takeda Cambridge
- Class Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Decreased libido; Female infertility; Pregnancy
Most Recent Events
- 30 Mar 2004 Paradigm Therapeutics is seeking an exclusive partner for GPR 54 modulators (http://www.paradigm-therapeutics.com)
- 30 Mar 2004 Preclinical trials in Decreased libido in United Kingdom (unspecified route)
- 30 Mar 2004 Preclinical trials in Female infertility in United Kingdom (unspecified route)